Wedge Capital Management L L P NC Sells 45,007 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wedge Capital Management L L P NC cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 23.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,778 shares of the biopharmaceutical company's stock after selling 45,007 shares during the quarter. Wedge Capital Management L L P NC's holdings in Amicus Therapeutics were worth $1,173,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Amicus Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock worth $275,619,000 after buying an additional 458,143 shares during the period. Wellington Management Group LLP grew its stake in Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after acquiring an additional 4,497,950 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Amicus Therapeutics by 4.4% during the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after acquiring an additional 159,139 shares in the last quarter. Northern Trust Corp raised its position in shares of Amicus Therapeutics by 5.9% during the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock worth $31,761,000 after purchasing an additional 187,652 shares during the period. Finally, Vestal Point Capital LP acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth approximately $31,557,000.

Amicus Therapeutics Stock Up 0.5%

NASDAQ:FOLD traded up $0.03 on Thursday, hitting $6.17. The stock had a trading volume of 3,856,594 shares, compared to its average volume of 2,968,940. Amicus Therapeutics, Inc. has a 1 year low of $5.81 and a 1 year high of $12.65. The firm's fifty day simple moving average is $6.49 and its two-hundred day simple moving average is $8.36. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a market cap of $1.90 billion, a P/E ratio of -34.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.54.

Analysts Set New Price Targets

A number of brokerages have commented on FOLD. Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Wells Fargo & Company decreased their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. The Goldman Sachs Group cut their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, UBS Group increased their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.